Trial Outcomes & Findings for Desipramine in Infantile Neuroaxonal Dystrophy (INAD). (NCT NCT03726996)
NCT ID: NCT03726996
Last Updated: 2020-10-14
Results Overview
The Gross Motor Function Measure (GMFM-66) is a 66 item standardized observational instrument designed and validated to measure change in gross motor function over time in children with cerebral palsy. Items are ordered in terms of difficulty and a unit of change has the same meaning throughout the scale ranging from 0 to 100. 0 = does not initiate, 1 = initiates, 2 = partially completes, 3 = completes. Scoring the GMFM-66 requires the use of a computer program called the Gross Motor Ability Estimator (GMAE). Individual item scores are entered and a mathematical algorithm calculates an interval level total score. The total score is an estimate of the child's gross motor function.
TERMINATED
PHASE4
4 participants
Baseline, 3, 6, 9, and 12 months
2020-10-14
Participant Flow
Participant milestones
| Measure |
Children With INAD
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
|
|---|---|
|
Overall Study
STARTED
|
4
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
4
|
Reasons for withdrawal
| Measure |
Children With INAD
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
|
|---|---|
|
Overall Study
Parent's decision
|
2
|
|
Overall Study
Study early termination
|
2
|
Baseline Characteristics
Data collected on one participant.
Baseline characteristics by cohort
| Measure |
Children With INAD
n=4 Participants
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
|
|---|---|
|
Age, Categorical
<=18 years
|
4 Participants
n=4 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=4 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=4 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
4 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
4 Participants
n=4 Participants
|
|
Gross Motor Function Measure (GMFM-66)
|
1 units on a scale
n=1 Participants • Data collected on one participant.
|
|
Quick Motor Function Test (QMFT)
|
0 units on a scale
n=1 Participants • Data collected on one participant.
|
PRIMARY outcome
Timeframe: Baseline, 3, 6, 9, and 12 monthsPopulation: No data collected beyond baseline.
The Gross Motor Function Measure (GMFM-66) is a 66 item standardized observational instrument designed and validated to measure change in gross motor function over time in children with cerebral palsy. Items are ordered in terms of difficulty and a unit of change has the same meaning throughout the scale ranging from 0 to 100. 0 = does not initiate, 1 = initiates, 2 = partially completes, 3 = completes. Scoring the GMFM-66 requires the use of a computer program called the Gross Motor Ability Estimator (GMAE). Individual item scores are entered and a mathematical algorithm calculates an interval level total score. The total score is an estimate of the child's gross motor function.
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Baseline, 3, 6, 9, and 12 monthsPopulation: No data collected beyond baseline.
The Quick Motor Function Test (QMFT) is a 16 item, psychometrically robust outcome assessment, validated in children and adults with Pompe disease (a lysosomal storage disorder characterized by progressive muscle weakness). This motor function test observes performance and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). If items can be performed on both left and right extremities, the right side is taken. A total score is obtained by adding the scores of all items. The total score ranges between 0 and 64 points. A higher score correlates with greater motor function.
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Baseline, 3, 6, 9, and 12 monthsPopulation: Data not collected.
The Vineland-3 is a standardized measure of adaptive behavior--the things that people do to function in their everyday lives. It is a norm-based instrument that compares the examinee's adaptive functioning in four domains: Communication, Daily Living Skills, Socialization and Motor Skills to that of others of the same age. A composite score of adaptive behavior is calculated that summarizes the individual's performance across all four domains.
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Baseline, 3, 6, 9, and 12 monthsPopulation: No data collected beyond 6 months.
Evidence of ECG changes, specifically, prolonged Q-T interval in response to study drug. The Q-T interval is the time from the start of the Q wave to the end of the T wave. It represents the time taken for ventricular depolarisation and repolarisation, effectively the period of ventricular systole from ventricular isovolumetric contraction to isovolumetric relaxation. Participants with a prolonged Q-T interval at any timepoint is reported.
Outcome measures
| Measure |
Children With INAD
n=4 Participants
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
|
|---|---|
|
Number of Participants With Change in Q-T Interval on ECG
|
1 Participants
|
PRIMARY outcome
Timeframe: Baseline, 3, 6, 9, and 12 monthsPopulation: No data collected beyond 6 months.
Transaminase values as measured by serum alanine transaminase (ALT) and aspartate transaminase (AST). Participants with abnormal transaminase values at any timepoint is reported.
Outcome measures
| Measure |
Children With INAD
n=4 Participants
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
|
|---|---|
|
Number of Participants With Abnormal Transaminase Values
|
0 Participants
|
Adverse Events
Children With INAD
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place